X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
WAL0921 is the first in class, proprietary, humanized monoclonal antibody that binds soluble urokinase plasminogen activator receptor, inhibiting the pro-inflammatory action that causes podocyte dysfunction and renal disease.
Lead Product(s): WAL0921
Therapeutic Area: Nephrology Product Name: WAL0921
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
Under the collaboration, Walden and U-M will analyze the effect in plasma of reducing suPAR levels seen in Walden’s single ascending dose study of WAL0921, first-in-class, proprietary, humanized monoclonal antibody that binds suPAR, in healthy subjects.
Lead Product(s): WAL0921
Therapeutic Area: Nephrology Product Name: WAL0921
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: University of Michigan
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration January 10, 2024
Details:
WAL0921 is the first in class, proprietary, humanized monoclonal antibody that binds soluble urokinase plasminogen activator receptor (suPAR), inhibiting the pro-inflammatory action that causes podocyte dysfunction and renal disease.
Lead Product(s): WAL0921
Therapeutic Area: Nephrology Product Name: WAL0921
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
U-M will collaborate with Walden Biosciences in connection with Dr. Hayek’s ongoing research in the area of suPAR and Walden will provide materials, data analysis, and may perform experiments to support the work, including the role of polymorphisms in the PLAUR gene.
Lead Product(s): Undisclosed
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: University of Michigan
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 05, 2022
Details:
Walden is seeking to develop breakthrough medicines that reverse the progression of both rare and common forms of kidney disease and restore renal function.
Lead Product(s): Undisclosed
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: ARCH Venture Partners
Deal Size: $51.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
